Abstract: The present invention relates to water-insoluble solid particles, especially pigments, which characteristically are coated with at least one layer of at least one product resulting from the reaction between at least one molecule capable of becoming hydrated in contact with water and at least one lipophilic molecule. It further relates to cosmetic, pharmaceutical and agricultural compositions comprising such particles and to the manufacture and use of said particles.

Abstract: This invention is directed to a novel solid matrixed controlled release, oral dosage form where the dosage form contains a therapeutically effective amount of a sulfonylurea or a salt or derivative thereof in the matrix. Further, the use of an aqueous alkalizing medium affords substantially complete bioavailability of the drug from the matrix of the tablet. The core tablets may optionally be coated with a coating material in the range of 2% to 10% with an enteric material or with a water insoluble material like ethyl cellulose.

Abstract: The present invention is for an oral osmotic controlled drug delivery system for a sparingly soluble drug comprising: a. a core comprising (i) finely particulate anhydrous carbamazepine (ii) a polymeric swelling agent consisting of one or more swellable hydrophilic polymers selected such that the polymeric swelling agent exhibits controlled swelling and the wall does not rupture or burst, (iii) a crystal habit modifier in whose presence, upon contact with an aqueous medium, the anhydrous carbamazepine being transformed into cuboidal or rod-shaped crystals of the dihydrate of carbamazepine, or mixtures thereof, and (iv) water-soluble compounds for inducing osmosis, b. a wall made of acylated cellulose which is impermeable to the components of the core, but permeable to water, and c. a passageway through the wall for releasing the components present in the core to the surrounding environment.

Abstract: Film-forming compositions are disclosed that can comprise, on a dry solids basis, 25 to 75 percent by weight of certain starch derivatives and 25 to 75% primary external plasticizer. The starch derivatives can be chemically modified starches that range in molecular weight from 100,000 to 2,000,000. The high levels of plasticizer in the films give excellent film flexibility and integrity.

Abstract: A solid composition for topical application comprising, in an aqueous phase, a gelling system comprising (i) gellan gum, (ii) at least one other hydrocolloid chosen from the group formed by xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, agar-agar, carrageenans, alginates, carob gum, guar gum, gum arabic, karaya gum, gum tragacanth, ghatti gum, pectins, gelatin, caseinates and hydroxypropylguar, and (iii) at least one amphiphilic polymer comprising at least one fatty chain and at least one hydrophilic unit.

Abstract: A composition for human consumption, comprising creatine and creatinine, the latter being in sufficient quantity to render creatine in an aqueous medium substantially stable, and a method of making the composition is provided.

Abstract: A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

Abstract: The invention concerns a cosmetic composition comprising in a cosmetically acceptable aqueous or hydroalcoholic medium, an aqueous dispersion of insoluble styling polymer particles, resulting in a mean fixing energy of styling material after drying on the keratinous fibers less than 200 microjoules in a fixing test. The invention is applicable to hair lacquers.

Abstract: Disclosed herein is a tableted oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: The present invention relates to substantially uniform, discontinuous films of a skin care product having a defined average particle size, particle spacing and coverage value. The films provide improved skin appearance, e.g., good apparent coverage and a natural look. The films can be formed by any method which provides the defined particle size, particle spacing and coverage value, including silk screening and the like and electrostatic spray techniques. The films are preferably formed by electrostatically spraying the composition onto the skin.

Abstract: This invention is directed to a new approach to form porous hydrogel materials by first creating gas pockets in the gel and then removing this gas. The removal of the gas creates a porous material, and the initial incorporation of sufficient gas allows one to create a material with an open, interconnected pore structure. Advantageous features of the resulting materials, in addition to their interconnected pore structure, may include that the pore structure is maintained over extended time periods and that the gels maintain a high mechanical integrity that allows seeding with cells and implantation without destruction or compression of the material.

Abstract: A gel system comprising propylene glycol alginate and basic aluminum acetate salt. Also, disclosed is a personal care formulation comprising a room deodorant gel employing said gel system.

Abstract: A range of products and methods are based on a creamy base of cream, artificial cream, thickened cream, cream cheese, mixtures thereof and mixtures with compatible incidental ingredients, the creamy base being aerated while cold and intimately mixed with a hot aqueous gelatin solution typically around 80° C. and providing 1-3% gelatin in the mixed product and the overrun in the aeration being typically in the range of 10-40%. Various further components are included or introduced with further processing selected from methods including heating the product with a further component to boiling point whereby de-aeration and enhanced shelf life is found in the resultant product. An alternative method is where flavor components are added prior to de-aeration. Another application is as a carrier for a pharmaceutical agent which is incorporated into the creamy base and protected with the gelatin matrix, a powder being formed ready for packaging in pharmaceutical doses.

Abstract: The present invention covers pourable liquid vehicles that can be combined with compositions, materials and substances. Among the benefits of such pourable liquid vehicles is the compositions are retained on the moistened surface for a period of time sufficient to allow compositions, materials and substances to act on said surface, resisting erosion or run-off from additional moisture being applied. Such pourable liquid vehicles have a number of utilities including but not limited to cleaning and treating surfaces of objects as well as biological or living organisms, including living creatures.

Abstract: The present invention relates to the preparation of orally administrable granules of hexahydropyrazine derivatives by mixing the active compound in the presence of suitable solvents with hydrophobic carriers, if appropriate in the presence of auxiliaries, and converting the resulting mixture, if appropriate, into other ready-to-use forms.

Abstract: Novel pharmaceutical formulations for treating a cellular proliferative disease are provided comprising: a therapeutically effective amount of a Golgi apparatus disturbing agent; a biocompatible carrier; and a solvent. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A (BFA) and the biocompatible carrier is a polymer such as chitin or chitosan. Methods of treating cellular proliferative diseases using the pharmaceutical formulations are also described.

Abstract: The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.

Abstract: A process for preparing free-flowing and, during handling, dust-free microparticles. The particles are at least 90% by weight, have a diameter of 100-400 &mgr;m, and contain one or more active ingredients in a glassy matrix. Generally, the process of the invention comprises the steps of (1) preparing an aqueous solution of the matrix materials, (2) mixing the flavor into the aqueous solution with stirring to form an emulsion or suspension, (3) spraying the emulsion in a spray drying tower under a supply of hot air to quickly create a semi-solid skin allowing outtake of moisture (water), and (4) subsequently subjecting the resulting particles to continued drying at lower temperatures in a fluid bed.

Abstract: The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

Abstract: A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose.

Abstract: A ligating band according to the present invention comprises an elastomeric layer and an inner drug releasing layer. The inner drug releasing layer includes a therapeutic agent, for example a chemotherapeutic agent for treating a mucosa, polyp or other growth. A ligating band according to the present invention also may include an inner diffusion barrier disposed between the elastomeric layer and the inner drug releasing layer, with the elastomeric layer and the inner drug releasing layer each contacting the inner diffusion barrier.

Abstract: A rapidly dispersing dosage form is described, which releases its active ingredients within a period of less than about ninety seconds. These dosage forms exhibit a three-dimensional shape that is retained for adequate storage but is readily dispersed in the presence of excess moisture. Also disclosed are methods of administration of a medicament and a process for the preparation of rapidly dispersing dosage forms.

Abstract: The present invention relates to a method for transferring one or more active ingredients between different phase carriers, which includes: (a) providing a solid, semi-solid, or nonaqueous liquid drug which contains at least one active ingredient; (b) admixing said drug with water or water solution to form an admixture; and (c) nebulizing said admixture to form liquid fine drops containing said active ingredient. This method enables the active ingredient stored in a solid phase carrier to transfer into an aqueous phase carrier, or enables the active ingredient stored in a non-aqueous liquid carrier to transfer into an aqueous phase carrier. The aqueous phase carrier contains the active ingredient can then be nebulized with a nebulizer by means of ultrasonic vibration. The present invention provides a new method for controlling administration by transferring the active ingredient between different phase carriers.

Abstract: A cosmetic consists of a cosmetic raw material in the form of an emulsion of silicone or organic oil containing crosslinked particles mixed with other cosmetic raw materials. Its touch on fingers and skin is good, spreading and feel during use are good, and it can also prevent unruly hair, stray hair, and tangling of hair, so hair can easily be arranged. It imparts a fresh, dry feeling without any stickiness. The cosmetic raw material consists of the silicone or organic oil emulsion containing crosslinked particles with a mean particle diameter of 0.05 to 100 &mgr;m. Crosslinking is obtained by an hydrosilylation of liquid crosslinkable compositions consisting of (A) organic compounds with at least two aliphatic unsaturated bonds per molecule, (B) silicon containing organic compounds with at least two hydrogen atoms bonded to silicon atoms in each molecule, and (C) hydrosilylation reaction catalysts.

Abstract: The present invention is directed to bioactive compositions that induce the repair of damaged or diseased connective tissues upon contact of the damaged or diseased tissues with the composition in vivo. More particularly the present invention is directed to the use of compositions comprising an effective amount of bone sialoprotein to enhance the repair of damaged or diseased bone.

Abstract: This invention relates to a stable aqueous dispersion of nutrients and more particularly, to an aqueous dispersions of an active nutritional ingredient selected form (a) an isoflavone, (b) lycopene (c) lutein, (d) a Coenzyme Qn where n is an integer of 1 to 12, or (e) a mixture of any of the foregoing nutrients.

Abstract: A method is provided for therapeutic use of a class of compounds that are effective in protecting nerve cells from deterioration and cell death arising from degenerative disease, trauma or aging and may be used to achieve a similar effect in male and female subjects with minimal adverse side effects. The method comprises administering a therapeutically effective dose of a natural or synthetic bioflavonoid that acts as an MAPK cascade antagonist. Examples of bioflavonoids that may be used in the present method are apigenin and 2-(2′-amino-3′ methoxyphenyl)-oxanaphthalen-4-one (PD098059).

Abstract: The present invention provides a method of attenuating the response of nociceptors to noxious stimuli by applying a composition comprising a hydrophilic foam substrate, a polymeric hydrophilic agent capable of absorbing water to the surface of the skin. In other aspects, the present invention provides a method of preventing the formation of a bruise in traumatized tissue, a method of attenuating swelling, a method of attenuating neurogenic inflammatory response, and a method of reducing the sensation of pain by applying like compositions to the surface of the skin of patients.

Abstract: The present invention provides a method of attenuating the formation of a bruise and a method of attenuating swelling or inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent capable of absorbing water to the surface of the skin.

Abstract: The present invention relates to novel insecticidal gel formulations for the controlled and sustained release of insecticidally active compounds by means of a heat source.

Abstract: Borate-diol reaction products for wound healing are disclosed. The product is obtained by reacting 0.01-1% by weight of borate with 1-10% by weight of a mixture polyvinyl alcohols. A 1% of the polyvinyl alcohols have viscosities of 25-30 mPa s and 3-10 mPa s.

Abstract: A purified shilajit composition is provided herein from native shilajit. The composition has an abundance of bioactive components, particularly, at least 0.3%, preferably 0.4-1%, by weight, oxygenated dibenzo-&agr;-pyrones and at least 60%, preferably 65-70%, by weight of fulvic acids of low-to-medium molecular weight ({overscore (M)}n of 700-2000) with an E4/E6 ratio of 8-10 at 465-665 nm, and whose 2% aqueous solution has a pH of ≧7. Personal care, pharmaceutical and nutritional use formulations of the purified shilajit composition also are described.

Abstract: This invention provides carrier systems useful in preparing pharmaceutical formulations, the systems comprising, by weight percentage, from about 1% to about 20%, preferably from about 5% to about 12%, of a surfactant component; from about 55% to about 93%, preferably from about 60% to about 85%, of a component of one or more polyethylene glycols (PEG); and from about 1% to about 25%, preferably from about 5% to about 15%, of one or more sucrose fatty acid esters or polyvinylpyrrolidone (PVP) with a K value between about 15 and about 90, preferably with a K value of from about 16 to about 18, most preferably about 17, as defined in USP/NF, or a combination of one or more sucrose fatty acid esters or PVP, and, optionally, one or more pharmaceutically acceptable preservatives or antioxidants, such as BHA, BHT, ascorbyl palmitate or benzyl alcohol.

Abstract: In order to provide a composition having a long gastroduodenal residence time and exhibiting an improved efficacy, is provided a gastrointestinal mucosa-adherent composition comprising an active ingredient and a material which swells a viscogenic agent capable of being viscous with water a (e.g. curdlan and/or a low-substituted hydroxypropylcellulose etc.).

Abstract: The invention relates to aqueous boron-containing compositions and their preparation. In particular the invention provides self-structured aqueous sodium pentaborate gels. The gels according to the invention may be prepared by reacting boric acid or boric oxide and sodium tetraborate or metaborate in suspension in water and under mixing such that a self-structured sodium pentaborate gel is formed. The gels according to the invention are physically stable and are easily handled.

Abstract: The present invention is directed to a solid sustained release pharmaceutical tablet for administering to a host, comprising a therapeutically effective amount of a pharmaceutically active ingredient and a sustained release carrier therefor, said sustained release carrier comprising (a) a hydrocolloid selected from the group consisting of xanthan gum, guar gum, and alginic acid or a pharmaceutically acceptable salt thereof, and (b) a cellulose ether, said hydrocolloid and cellulose ether being present in synergistic effective amounts to retard release of said pharmaceutically active ingredient, said hydrocolloid being present in amount ranging from about 0.3% to about 7.0% by weight of the tablet and said cellulose ether being present in an amount ranging from 3% to about 20% of said tablet, and said cellulose ether being present in said carrier in amounts equal to or greater than 33% by weight and said carrier being present in amounts less than 35% by weight of said tablet.

Abstract: The present invention relates to a pharmaceutical controlled-release oral drug delivery system comprising as active ingredient at least one &bgr;-lactam antibiotic agent, having a specific absorption site in the small intestine in combination with a polymeric matrix, optionally further containing additional pharmaceutically acceptable constituents, wherein at least 50% of the &bgr;-lactam antibiotic agent are released from the matrix within from about 3 to about 4 hours from oral administration and the reminder of the pharmaceutical agent is released at a controlled rate. The drug delivery system according to the invention optionally further comprises a &bgr;-lactamase inhibitor, preferably in combination with amoxicillin and/or amoxicillin trihydrate as the active ingredient. The polymeric matrix of the pharmaceutical controlled-release oral drug delivery system of the invention my be of hydrophilic and/or hydrophobic nature and the delivery system may further comprise pharmaceutically acceptable additive.

Abstract: The present invention provides carboxamine compounds, methods and compositions for inhibiting PARP activity.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of ore or more aquatic organisms in a column of water. The complexes comprise a least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials. The components are selected to sink or float so that the complexes will permeate and/or remain in any planar or volumetric segment of a water column for a period of time that is sufficient to effectively treat a population of aquatic organisms.

Abstract: A method for preparing a hydroxyapatite composite is disclosed. This method comprises alternately soaking a matrix which has been made hydrophilic at least on its surface, in a calcium ion aqueous solution containing calcium ions and substantially free of phosphate ions and in a phosphate ion aqueous solution containing phosphate ions and substantially free of calcium ions to securely form hydroxyapatite at least on the surface of the matrix. Also disclosed is a biocompatible material composed of the hydroxyapatite composite obtained by the method.

Abstract: Cosmetic or pharmaceutical formulations such as (a) anhydrous cosmetic stick formulations and (b) anhydrous aerosol spray formulations, comprising an organic dispersion medium having particles dispersed therein, which particles are preferably prepared by a process comprising spray-drying a mixture of liposome encapsulated active agent, modified starch, and optionally a hydrocolloid gum such as maltodextrin.

Abstract: An insect-repelling agent contains N,N-diethyl-m-toluamide (DEET) based on alcohol solutions as the active ingredient (repellent), and further contains an adjuvant that extends the period of effectiveness of DEET following application to human skin. It is proposed that the sole adjuvant is glycerol in an amount of more than 10 percent by weight of the insect-repelling.

Abstract: Film-forming compositions are disclosed that can comprise, on a dry solids basis, 25 to 75 percent by weight of certain starch derivatives having a DE less than about 1, 25 to 75% plasticizer, and 0.1 to 15% hydrocolloid gum. The starch derviatives can be chemically modified starches which range in molecular weight from 100,000 to 2,000,000. These starch-based systems can completely replace gelatin in edible film-forming applications such as soft and hard gel capsules.

Abstract: Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions. The compositions of the present invention may also be combined with materials capable of forming seals over ulcers or lesions to further promote the healing process.

Abstract: A dehydrated hydrogel incorporating a plasticiser and fibers which have provided cations for cross-linking the dehydrated hydrogel.

Abstract: An sodium ion absorption inhibitor, a sodium ion excretion accelerator and an agent for preventing and treating a disease caused by excessive common salt ingestion, each of which comprising a metal salt (excluding sodium salt) of lambda-carrageenan as an active ingredient, can excrete excessively ingested common salt outside the body positively and safely, and particularly have excellent action in excreting the sodium ions into feces.

Abstract: A method of imparting water resistance to a molded polysaccharide having poor water resistance because of its high hydrophilicity, which comprises bonding a prolamin such as zein to the surface of the molded polysaccharide.

Abstract: A soft capsule comprising a wall derived from a multilayer film that comprises three layers. The layers are an innermost sealing plasticized hydroxypropyl methyl cellulose, an adhesion promoting layer of propylene glycol alginate and a barrier layer of sodium alginate.

Abstract: Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of one or more aquatic organisms in a column of water. The complexes comprise at least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials. The components are selected to sink or float so that the complexes will permeate and/or remain in any planar or volumetric segment of a water column for a period of time that is sufficient to effectively treat a population of aquatic organisms.